Patrick Heron


Patrick Heron is a managing general partner of Frazier’s Life Sciences team. He joined the firm in 1999 and opened Frazier’s Menlo Park office in 2003. Heron has successfully partnered with entrepreneurs across a range of company types and stages- from early-stage anti-infectives companies to more than $100 million commercial-stage dermatology companies. Heron has also been active in company formation around both early and later stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), Trubion (acquired by EBS), MedPointe (acquired by Meda) and Cidara (NASDAQ: CDTX).  He currently serves on the boards of Collegium, Imago, Iterum, Nexcida, Silvergate, Tobira and VentiRx. Prior to joining Frazier Healthcare Partners, Heron helped develop McKinsey & Company’s west coast biotechnology consulting practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering and research prioritization. Heron received his master’s degree in business from Harvard Business School. He also holds a bachelor’s degree from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.